Patents Examined by Lynn A. Bristol
  • Antibodies and chimeric antigen receptors specific for ROR1
    Patent number: 11919970
    Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 5, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
  • Therapeutic agent for cancer
    Patent number: 11911348
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: February 27, 2024
    Assignee: THERAVALUES CORPORATION
    Inventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
  • BCMA monoclonal antibody-drug conjugate
    Patent number: 11912782
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: February 27, 2024
    Assignee: MedImmune, LLC
    Inventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
  • Anti-Siglec-7 antibodies having reduced effector function
    Patent number: 11912766
    Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies that have reduced effector function.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: February 27, 2024
    Assignee: Allakos, Inc.
    Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic
  • Antibody binding specifically to CD40 and use thereof
    Patent number: 11905331
    Abstract: The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: February 20, 2024
    Assignee: KUMHO HT, INC.
    Inventors: Gil Yong Ji, Kwon Pyo Hong, Eui Sup Lee, Yoo Ri Moon, Sangsoon Yoon
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Patent number: 11891454
    Abstract: The present invention describes hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 6, 2024
    Assignee: Ichnos Sciences SA
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Antibody constructs for MSLN and CD3
    Patent number: 11884720
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: January 30, 2024
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
  • Compositions and methods related to IL27 receptor binding
    Patent number: 11873349
    Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 16, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick Lupardus, Deepti Rokkam
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 11873339
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: January 16, 2024
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
    Patent number: 11866507
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: January 9, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, John C. Timmer
  • IL-17 receptor A antigen binding proteins
    Patent number: 11858999
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: January 2, 2024
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Humanization of rabbit antibodies using a universal antibody framework
    Patent number: 11858981
    Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Leonardo Borras, David Urech
  • Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
    Patent number: 11851476
    Abstract: It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 26, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Taichi Kuramochi, Meiri Kawazoe, Naoka Hironiwa, Tomoyuki Igawa
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Patent number: 11851502
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 26, 2023
    Assignee: Ichnos Sciences SA
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Anti-CD3-folate conjugates and their uses
    Patent number: 11851488
    Abstract: Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 26, 2023
    Assignee: Ambrx, Inc.
    Inventors: Harun Rashid, Feng Tian, Marco Gymnopoulos
  • Bispecific antibodies with specific binding to CD47 and PD-L1
    Patent number: 11840567
    Abstract: The present invention relates to the field of bioengineering, specifically to antibodies or their antigen-binding fragments, and to the use thereof. More particularly, the present invention relates to antibodies that bind specifically to CD47 and PD-L1. The invention also relates to a nucleic acid that codes for the given antibody or for the antigen-binding fragment thereof, to an expression vector, to a method of producing the antibody, and to a use of the aforementioned antibodies and compositions in cancer treatment.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: December 12, 2023
    Inventors: Kirill Vladimirovich Solovyev, Andrei Borisovich Ulitin, Timofey Aleksandrovich Nemankin, Valery Vladimirovich Solovyev, Dmitry Valentinovich Morozov
  • CAR-T cells targeting IL-1RAP and their use
    Patent number: 11839630
    Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 12, 2023
    Assignees: ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE, CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON, UNIVERSITE DE FRANCHE COMTE
    Inventors: Christophe Ferrand, Marina Deschamps, Fabrice Larosa
  • Anti-TIM-3 antibodies and methods of use thereof
    Patent number: 11839653
    Abstract: Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: December 12, 2023
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • Human antibodies to human delta like ligand 4
    Patent number: 11820815
    Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston